US curb on Indian biopharma firms
August 13, 2009 11:44 am
Indian biopharmaceutical companies are likely to face more hurdles in the US. This is on the back of the US Senate Health, Education, Labour & Pensions Committee approving an amendment that will protect biotech developers from generic competition for 12 years. Though the amendment is yet to be approved by the Congress, if it is passed in its current form, will deal a huge blow to Indian companies engaged in research and manufacture of biosimilar drugs. Biosimilar drugs are similar versions of biotech drugs, akin to generics being copies of chemical drugs.
Your future advertising space? Our media data